q2K BHP
Black History Portal
THE BHP WIRE —
HIDDEN TRUTHS
What's New!
THE JOURNEY THROUGH TIME

Explore Black History

Explore the people, places, events, achievements, struggles and stories that shaped our journey.

✊🏾

Civil Rights

Movements, leaders, victories and the continuing fight for equality.

⚙️

Black Inventors

Innovation, patents, science, technology and world-changing contributions.

🏆

Sports

Pioneers, champions, Negro Leagues, records, activism and excellence.

♟️

People

Meet the people whose lives, choices and achievements shaped the journey.

📍

Places

Black towns, communities, institutions and places where history happened.

📜

Events

Moments that changed communities, movements, institutions and the nation.

Enter a person, place, event, or topic.
MY'STORY

The MOVE Fire

This is a personal recollection on the Move fire on May 13, 1985 Philadelphia police fired thousands of rounds at the MOVE house, city officials approved dropping an explosive device on the roof, the resulting fire was allowed to burn, 11 people—including five children—died, and 61 homes were destroyed. Philadelphia City Council later called it a “brutal attack carried out by the City of Philadelphia on its own citizens” and acknowledged that no individual faced criminal consequences for the bombing. One timeline correction worth preserving for the BHP record: the major previous MOVE-police confrontation was August 8, 1978, about seven years before the bombing, not a year or two earlier. Officer James Ramp was killed, other police and firefighters were wounded, nine MOVE members were later convicted, and television cameras recorded police beating Delbert Africa during his arrest. The 1985 MOVE Commission later specifically criticized city planners for failing to adequately use lessons from that 1978 confrontation. And that actually strengthens the point you’re making: 1985 did not happen without precedent or institutional memory. There had already been a deadly confrontation with MOVE, years of conflict, negotiations and police involvement before Osage Avenue.

MORE →
BLACK FACTS
The Truths They Never Taught You...

Ruler of the Mali Empire in the 14th century

Mansa Musa was the ruler of the Mali Empire in West Africa. Details recorded here should be sourced; unknown information is left blank.

MORE →
BHP gathered finds from its connected research sources. Showing the 4 strongest Black History matches.
← BACK TO RESULTS
Wikipedia

Nereus Pharmaceuticals

Nereus Pharmaceuticals
TypePrivate
IndustryPharmaceuticals
FoundedSan Diego, California, United States (1988)
FounderMichael A. Palladino, Kobi M. Sethna, Stan Fleming, William Fenical
HeadquartersSan Diego, California, United States
Key peopleMichael A. Palladino Ph.D.(Scientific Co-founder, SVP and Chief Technology Officer) Kobi M. Sethna (President, CEO)[1]
Gary Shearman (Chairman of the Board)[2]
G.
Number of employees
36[3]
Websitewww.nereuspharm.com

Nereus Pharmaceuticals was a pharmaceutical company focused on the development of natural products from marine microbial and other natural sources into small molecule human therapeutics.[4] The major disease area addressed by Nereus is cancer. Nereus was purchased by Triphase Research and Development in 2012.[5]

Drug discovery

[edit]

Until 2004, Nereus used methods licensed from the University of California, San Diego to retrieve and cultivate marine microorganisms, particularly bacteria in the Actinomycetia class and organisms belonging to Kingdom Fungi.[4] Since 2004, the company has focused on commercializing identified bioactive natural products.[4] As of mid-2007, two compounds were being examined in Phase I clinical trials: NPI-2358 and NPI-0052.[4]

  • Plinabulin (NPI-2358) is a halimide derivative, halimide itself having been isolated from a member of genus Aspergillus.[4][6] This compound appears to selectively disrupt tumour vasculature through interaction with microtubules.[4]
  • NPI-1342 (Acanthoic Acid analog, NPI-1302a-3) is a plant derived orally active small molecule that targets the NF_kB transcript factor pathway. It is significantly active against cancer and inflammatory diseases and is being developed for clinical testing in multiple myeloma and glioblastoma.
  • Salinosporamide A (NPI-0052) is a natural product of Salinispora tropica, a member of the bacterial family Micromonosporaceae that was first isolated in 2002 and taxonomically identified genetically in 2005.[7] NPI-0052 acts as a proteasome inhibitor.[4]

References

[edit]
  1. ^ "Executive Team". Nereus Pharmaceuticals. Archived from the original on 2008-01-08. Retrieved 2008-01-20.
  2. ^ "Board of Directors". Nereus Pharmaceuticals. Archived from the original on 2008-01-08. Retrieved 2008-01-20.
  3. ^ "Company Overview". Nereus Pharmaceuticals. Archived from the original on 2008-01-08. Retrieved 2008-01-19. Number of employees - 36
  4. ^ a b c d e f g Carol Potera (2007-06-15). "Nereus Prospects Oceans for Cancer Drugs". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. Retrieved 2008-01-19. Nereus mines microorganisms collected from the ocean to find new small molecule drug candidates, much like older pharmaceutical companies discovered new drugs by screening soil.
  5. ^ "Pharma commercial intelligence, news & analysis - Evaluate". www.evaluate.com.
  6. ^ US 6069146, Fenical, William; Jensen, Paul R. & Cheng, Xing C., "Halimide, a cytotoxic marine natural product, and derivatives thereof", published 2000-05-30, assigned to The Regents of the University of California 
  7. ^ Luis A., Maldonado; W. Fenical; P. R. Jensens; C. A. Kauffman; et al. (2005-04-15). "Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae". International Journal of Systematic and Evolutionary Microbiology. 55 (5). Society for General Microbiology: 1759–1766. doi:10.1099/ijs.0.63625-0. PMID 16166663. Retrieved 2008-01-19. Isolated from coarse sand off the Bahamas. The type strain is CNB-440T (=ATCC BAA-916T=DSM 44818T). (from Results & Discussion section)

Source: Wikipedia. Article content is retrieved live through the MediaWiki API.

No preview image
Wikipedia

Nereus Pharmaceuticals

Nereus Pharmaceuticals was a pharmaceutical company focused on the development of natural products from marine microbial and other natural sources into small molecule human therapeutics. The major disease area addressed by Nereus is cancer. Nereus was purchased by Triphase Research and Development in 2012.

MORE →
Wikipedia

Tradipitant

Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). It is a neurokinin 1 receptor antagonist. It works by blocking substance P, a small signaling molecule. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. Tradipitant was approved for medical use in the United States in December 2025.

MORE →
No preview image
Wikipedia

Nereus (disambiguation)

Nereus, in Greek mythology, was the eldest son of Pontus and Gaia. Nereus may also refer to:

MORE →
Wikipedia

Motion sickness

Motion sickness occurs due to a difference between actual and expected motion. Symptoms commonly include nausea, vomiting, cold sweat, headache, dizziness, tiredness, loss of appetite, and increased salivation. Complications may rarely include dehydration, electrolyte problems, or a lower esophageal tear. The cause of motion sickness is either real or perceived motion. This may include car travel, air travel, sea travel, space travel, or reality simulation. Risk factors include pregnancy, migraines, and Ménière's disease. The diagnosis is based on symptoms. Treatment may include behavioral measures or medications. Behavioral measures include keeping the head still and focusing on the horizon. Three types of medications are useful: antimuscarinics such as scopolamine, H1 antihistamines such as dimenhydrinate, and amphetamines such as dexamphetamine. Side effects, however, may limit the use of medications. A number of medications used for nausea (antiemetics) such as ondansetron are not effective for motion sickness. Many people can be affected with sufficient motion and nearly everyone will experience motion sickness at least once in their lifetime. Susceptibility, however, is variable, with about one-third of the population being susceptible while other people can be affected only under very extreme conditions. Women can be more easily affected than men. Motion sickness has been described since at least the time of Homer (c. eighth century BC).

MORE →
TOPIC OF THE DAY

Greenwood / Black Wall Street

Before the 1921 destruction of Tulsa’s Greenwood District, Black residents had created a remarkable center of business and community life. The district included stores, professional offices, entertainment venues and homes owned by Black citizens. Understanding Greenwood means learning what was built—not only what was burned.

MORE →
TRIVIA QUESTION OF THE DAY

Which Black woman became the first elected to the United States Congress?

Shirley Chisholm, elected in 1968.